Tudor Investment Corp ET AL Acquires New Stake in USANA Health Sciences, Inc. (NYSE:USNA)

Tudor Investment Corp ET AL acquired a new position in shares of USANA Health Sciences, Inc. (NYSE:USNA) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 9,506 shares of the company’s stock, valued at approximately $341,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Pzena Investment Management LLC lifted its position in USANA Health Sciences by 3.6% in the fourth quarter. Pzena Investment Management LLC now owns 1,087,076 shares of the company’s stock valued at $39,015,000 after purchasing an additional 37,466 shares during the period. Principal Financial Group Inc. lifted its holdings in shares of USANA Health Sciences by 2.8% in the 4th quarter. Principal Financial Group Inc. now owns 53,603 shares of the company’s stock valued at $1,924,000 after buying an additional 1,480 shares during the period. Rhumbline Advisers boosted its stake in shares of USANA Health Sciences by 39.8% in the fourth quarter. Rhumbline Advisers now owns 49,390 shares of the company’s stock valued at $1,773,000 after buying an additional 14,068 shares in the last quarter. Norges Bank acquired a new stake in USANA Health Sciences in the fourth quarter valued at $953,000. Finally, Dimensional Fund Advisors LP lifted its holdings in USANA Health Sciences by 7.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 773,228 shares of the company’s stock valued at $27,751,000 after acquiring an additional 55,059 shares during the period. Hedge funds and other institutional investors own 54.25% of the company’s stock.

Insider Buying and Selling at USANA Health Sciences

In other news, CEO Jim Brown sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $29.47, for a total value of $147,350.00. Following the completion of the transaction, the chief executive officer now owns 15,716 shares of the company’s stock, valued at $463,150.52. The trade was a 24.14 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider David Mulham Mulham sold 3,234 shares of the firm’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $32.98, for a total transaction of $106,657.32. Following the sale, the insider now owns 12,775 shares in the company, valued at approximately $421,319.50. This trade represents a 20.20 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 16,594 shares of company stock worth $520,384. 0.63% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the stock. DA Davidson lowered their price target on shares of USANA Health Sciences from $38.00 to $36.00 and set a “neutral” rating on the stock in a research note on Thursday, February 27th. Sidoti downgraded shares of USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 18th. Finally, StockNews.com cut USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a report on Friday, February 14th.

USANA Health Sciences Stock Up 1.2 %

Shares of USNA stock opened at $29.52 on Friday. The stock has a market cap of $549.75 million, a P/E ratio of 10.43, a P/E/G ratio of 0.93 and a beta of 0.60. USANA Health Sciences, Inc. has a fifty-two week low of $23.10 and a fifty-two week high of $49.78. The business has a fifty day simple moving average of $27.34 and a 200-day simple moving average of $32.71.

USANA Health Sciences (NYSE:USNA) last posted its earnings results on Tuesday, April 22nd. The company reported $0.73 earnings per share for the quarter, beating the consensus estimate of $0.70 by $0.03. The firm had revenue of $249.54 million during the quarter, compared to the consensus estimate of $243.08 million. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.64%. During the same period last year, the firm posted $0.86 EPS. On average, sell-side analysts anticipate that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current year.

USANA Health Sciences Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.